BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36944297)

  • 1. The promise of metabolic imaging in diffuse midline glioma.
    Lovibond S; Gewirtz AN; Pasquini L; Krebs S; Graham MS
    Neoplasia; 2023 May; 39():100896. PubMed ID: 36944297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a machine learning algorithm for predicting diffuse midline glioma, H3 K27-altered, H3 K27 wild-type high-grade glioma, and primary CNS lymphoma of the brain midline in adults.
    Lv K; Chen H; Cao X; Du P; Chen J; Liu X; Zhu L; Geng D; Zhang J
    J Neurosurg; 2023 Aug; 139(2):393-401. PubMed ID: 36681946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indolent presentation of a diffuse midline glioma, H3 K27-altered.
    Damodharan S; Helgager J; Puccetti D
    Childs Nerv Syst; 2023 Mar; 39(3):833-835. PubMed ID: 36094605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered.
    Zhao JP; Liu XJ; Lin HZ; Cui CX; Yue YJ; Gao S; Xu HZ
    BMC Neurol; 2022 Dec; 22(1):498. PubMed ID: 36550486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
    Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
    Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
    Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
    Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
    Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct MRI characteristics of spinal cord diffuse midline glioma, H3 K27-altered in comparison to spinal cord glioma without H3 K27-alteration and demyelination disorder.
    Ying Y; Liu X; Li X; Mei N; Ruan Z; Lu Y; Yin B
    Acta Radiol; 2024 Mar; 65(3):284-293. PubMed ID: 38115811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures.
    Banan R; Akbarian A; Samii M; Samii A; Bertalanffy H; Lehmann U; Hartmann C; Brüning R
    PLoS One; 2021; 16(8):e0249647. PubMed ID: 34347774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
    Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
    Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
    Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
    J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
    Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
    Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
    Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
    Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rare presentation of a spinal diffuse midline glioma in a child: a case report.
    Isfaoun Z; Laasri K; Jidal M; Cherradi N; Melhaoui A; Chat L; Haddad SE; Kababri ME; Khorassani ME; Kili A; Ansari NE; Hessissen L
    Pan Afr Med J; 2023; 44():183. PubMed ID: 37484594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.